Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junxiang Peng

Showing results (41-50 of 42) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 42 results.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 30, 2026
Activating ZBP1-centered PANoptosis and a collaborative innate-adaptive immune response sensitizes glioblastoma to PD-1 blockadeYonghua Cai, Ziyi Luo, Zhengming Zhan, et al.
Acta Neuropathologica Communications|March 3, 2025
Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutationYilamujiang Ainiwan, Haomin Li, Yongjia Zheng, et al.
Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 42 results.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 30, 2026
Activating ZBP1-centered PANoptosis and a collaborative innate-adaptive immune response sensitizes glioblastoma to PD-1 blockadeYonghua Cai, Ziyi Luo, Zhengming Zhan, et al.
Acta Neuropathologica Communications|March 3, 2025
Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutationYilamujiang Ainiwan, Haomin Li, Yongjia Zheng, et al.
Pageof 5